Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for BridgeBio Pharma, Inc. (BBIO), each with what it measures. Figures are trailing twelve months or the most recent reported period.
Valuation
Metric
Value
P/E ratioShare price divided by earnings per share.
-18.92
P/B ratioShare price divided by book value per share.
-5.27
P/S ratioMarket value divided by annual revenue.
18.57
PEG ratioP/E divided by the earnings growth rate.
-1.47
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.
-24.64
EV / RevenueEnterprise value against annual revenue.
21.12
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.
-5.38%
Free cash flow yieldFree cash flow as a percentage of market value.
-3.32%
Profitability
Metric
Value
Gross marginRevenue left after the direct cost of goods sold.
93.35%
Operating marginRevenue left after operating costs.
-76.22%
Net marginRevenue left after every cost, including tax and interest.
-97.64%
Return on equityProfit as a percentage of shareholders’ equity.
31.67%
Return on assetsProfit as a percentage of total assets.
-57.20%
Return on capital employedOperating profit against the capital the business uses.
-166.38%
Financial health
Metric
Value
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.
1.23
Quick ratioThe same, excluding inventory.
1.17
Cash ratioCash alone against current liabilities.
1.98
Debt to equityTotal borrowings against shareholders’ equity.
-0.99
Debt to assetsTotal borrowings against total assets.
2.92
Interest coverageHow many times operating profit covers the interest bill.
-6.05
Per share and size
Metric
Value
Earnings per shareProfit attributable to each share.
$-3.79
Book value per shareShareholders’ equity divided by shares outstanding.
$0.00
Shares outstandingShares currently issued.
0
Market capitalisationShare price times shares outstanding.
$13.40B
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.
$15.06B
EmployeesReported headcount.
839
Dividend
Metric
Value
Dividend yieldAnnual dividend as a percentage of the share price.
0.00%
BridgeBio Pharma, Inc. (BBIO) statistics — frequently asked questions
What is BridgeBio Pharma, Inc.'s P/E ratio?
BridgeBio Pharma, Inc. (BBIO) trades on a price-to-earnings ratio of -18.92. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.
What is BridgeBio Pharma, Inc.'s return on equity?
BridgeBio Pharma, Inc. (BBIO) reports a return on equity of 31.67%, meaning it generated that much profit for every dollar of shareholders' equity.
How much debt does BridgeBio Pharma, Inc. carry?
BridgeBio Pharma, Inc. (BBIO) has a debt-to-equity ratio of -0.99, which compares total borrowings with shareholders' equity.
What is BridgeBio Pharma, Inc.'s profit margin?
BridgeBio Pharma, Inc. (BBIO) keeps -97.64% of revenue as net profit after every cost, including tax and interest.